Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Shukra Pharmaceuticals Ltd
Your Vote -
Buy
58.33%
Hold
16.67%
Sell
25.00%
58.33%
12 users have voted
Option Chain
Analyzes market sentiment, predicts Shukra Pharmaceuticals Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Shukra Pharma. - Update on board meeting
-
Shukra Pharma. - Board Meeting Intimation for Unaudited Financial Result For The Third Quarter Ended On 31 December, 2025 Alo
-
Shukra Pharma. - Announcement under Regulation 30 (LODR)-Allotment
-
Shukra Pharma. - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On Today
-
Shukra Pharma has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2025
-
Shukra Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Shukra Pharma - Voting Result Along With Scrutinizer Report Of Postal Ballot
-
Shukra Pharma - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
-
Shukra Pharma - Reconstitution Of Committees Of The Company.
-
Shukra Pharma - Announcement under Regulation 30 (LODR)-Change in Management
-
Shukra Pharma - Announcement under Regulation 30 (LODR)-Resignation of Director
-
Shukra Pharma - Board Meeting Outcome for Outcome Of Meeting Of Board Of Directors Held On December 30, 2025.
-
Shukra Pharma - Intimation For Corporate Announcement Under Regulation 30 Of SEBI (LODR) Regulations, Working In The Governme
-
Shukra Pharma - Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
-
Shukra Pharma - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
-
Shukra Pharma - Approval Of Continuation Of Directorship Of Mr. Jitendra Somchand Shah Non-Executive Independent Director Who
-
Shukra Pharma - Outcome Of The Meeting Of The Board Of Directors Held On Saturday, November 29, 2025
-
Shukra Pharma - Board Meeting Outcome for Outcome Of The Meetins Of The Board Of Directors Held On Saturdav. November\r\n29.2
-
Shukra Pharma Q2 net profit zooms 340.74% at Rs 2.38 cr
-
Shukra Pharma - Un-Audited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30, 2025, Al
-
Shukra Pharma - Board Meeting Outcome for Outcome Of Board Meeting Held On November 13, 2025.
-
Shukra Pharma - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 -
Key fundamentals
Evaluate the intrinsic value of Shukra Pharmaceuticals Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 67.0125 | 60.7935 | 30.3783 | 19.7265 | 25.3697 |
| Liabilities | 67.0125 | 60.7935 | 30.3783 | 19.7265 | 25.3697 |
| Equity | 43.7879 | 10.947 | 3.9142 | 1.5657 | 1.5656 |
| Gross Profit | 12.7297 | 19.4033 | 5.3633 | 2.8857 | 1.4438 |
| Net Profit | 9.5751 | 18.5372 | 4.4065 | 0.7507 | 0.0338 |
| Cash From Operating Activities | 7.9184 | -5.1967 | 3.1695 | 7.7843 | 0.3715 |
| NPM(%) | 29.38 | 24.85 | 7.48 | 3.66 | 0.3 |
| Revenue | 32.5873 | 74.5729 | 58.8337 | 20.486 | 11.196 |
| Expenses | 19.8576 | 55.1696 | 53.4704 | 17.6003 | 9.7521 |
| ROE(%) | 14.55 | 28.16 | 6.69 | 1.14 | 0.05 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Shukra Pharmaceuticals Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 687.60 | 0.34 | 0.00 | 22.67 | 301.39 | 0.73 |
| Lotus Eye Hospital and Institute Ltd | 121.75 | -4.99 | 381.53 | 82.62 | 3.55 | 0.00 |
| Bharat Immunological and Biologicals Corporation Ltd | 19.19 | 3.45 | 0.00 | 171.55 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 591.60 | 4.87 | 0.00 | 77.92 | -604.77 | 0.00 |
Company Info
1998 - Mrs. Riddhi M Patel, director of the company retires by rotation as per Provisions of the Act at this Annual General Meeting. 1999 - In accordance with the Companies Act, 1956 and Articles of Association of the Company, Mr. Mihir M Patel retire by rotation and is eligible for re-appointment. - Company has installed modern energy efficient machines. 2023 -Company issued rights shares of Rs. 10 in the ratio of 6:1 at a premium of Rs. 10 per share. 2024 -The Company has issued Bonus Shares in the Ratio of 3:1.
1998 - Mrs. Riddhi M Patel, director of the company retires by rotation as per Provisions of the Act at this Annual General Meeting. 1999 - In accordance with the Companies Act, 1956 and Articles of Association of the Company, Mr. Mihir M Patel retire by rotation and is eligible for re-appointment. - Company has installed modern energy efficient machines. 2023 -Company issued rights shares of Rs. 10 in the ratio of 6:1 at a premium of Rs. 10 per share. 2024 -The Company has issued Bonus Shares in the Ratio of 3:1.
Read More
Parent Organisation
Shukra Pharmaceuticals Ltd.
Founded
04/03/1993
Managing Director
Mr.Dakshesh Rameshchandra Shah
NSE Symbol
FAQ
The current price of Shukra Pharmaceuticals Ltd is
The 52-week high for Shukra Pharmaceuticals Ltd is
The market capitalization of Shukra Pharmaceuticals Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Shukra Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Shukra Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Shukra Pharmaceuticals Ltd shares.
The CEO of Shukra Pharmaceuticals Ltd is Mr.Dakshesh Rameshchandra Shah, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
